A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
A phase 1/2 trial of Bevacizumab in advanced solid tumours, run by Bristol-Myers Squibb, active and no longer recruiting.
Overview
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06730750 by Bristol-Myers Squibb, with 360 participants enrolled, started 2025-02-12 and due to reach its primary completion in 2026-09-05. Interventions recorded: BMS-986490 and Bevacizumab.
Similar pages
not linked directly; found by shared links- TrialA Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Shares Bevacizumab, Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialS-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
Shares Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors
Shares Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Shares Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
Shares Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.